News for Sonnet BioTherapeutics Holdings, Inc. (SONN)

Shares of Box, Inc. BOX rose sharply in today's pre-market trading after the company posted better-than-expected first-quarter results and raised its FY2026 gui...

PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN) (the "Company" or "Sonnet"), a clinical-stage company developin

\n Sonnet BioTherapeutics (SONN) reports positive safety results for SON-1010 combined with atezolizumab. The results are from a Phase 1b/2a clinical trial

**media[596956]**

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (

**media[583202]**

**media[582622]**

**media[577395]**

Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-1

On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the ”œCompany” or ”

**media[551159]**

Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, A

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the ”œCompany” or ”œSonnet”) ( SONN), a clinical-stage company

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in

**media[520657]**

PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the ”œCompany” or ”œSonnet”) ( SONN), a clinical-stage company d

**media[499686]**

**media[494623]**

PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (SONN), a clinical-stage company developing